Provectus Biopharmaceuticals, Inc. (PVCT) stock
PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Provectus Biopharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Provectus Biopharmaceuticals's profit margin for the twelve months ending Dec 31, 2025 was -1615.8%. For fiscal 2025 it was -1615.8%, against -766.9% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1615.8% | −849.0 |
| FY2024 | Dec 31, 2024 | -766.9% | −210.7 |
| FY2023 | Dec 31, 2023 | -556.2% | −196.8 |
| FY2022 | Dec 31, 2022 | -359.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | -3156.6% | −2824.5 |
| Q1 FY2025 | Mar 31, 2025 | -409.2% | −197.5 |
| Q4 FY2024 | Dec 31, 2024 | -16517.7% | −15969.9 |
| Q3 FY2024 | Sep 30, 2024 | -924.3% | +188.3 |
| Q2 FY2024 | Jun 30, 2024 | -332.1% | +183.9 |
| Q1 FY2024 | Mar 31, 2024 | -211.7% | +191.9 |
| Q4 FY2023 | Dec 31, 2023 | -547.8% | −103.3 |
| Q3 FY2023 | Sep 30, 2023 | -1112.6% | −886.1 |
| Q2 FY2023 | Jun 30, 2023 | -516.0% | −180.9 |
| Q1 FY2023 | Mar 31, 2023 | -403.6% | +145.9 |
| Q4 FY2022 | Dec 31, 2022 | -444.5% | – |
| Q3 FY2022 | Sep 30, 2022 | -226.5% | – |
| Q2 FY2022 | Jun 30, 2022 | -335.0% | – |
| Q1 FY2022 | Mar 31, 2022 | -549.5% | – |
See a number that looks wrong?